Sponsored Content
Intercell: Vaccine Development to Suspend
Sponsored Content
Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710. The share of Intercell crashed seriously.

Merck, known as MSD outside the United States and Canada, and Intercell AG today announced that following a pre-specified interim analysis from the Phase II/III clinical trial evaluating V710, an investigational vaccine for the prevention of Staphylococcus aureus (S. aureus) infection, the independent Data Monitoring Committee (DMC) recommended suspension of enrollment.
Although…
or Log In
Sponsored Content
Sponsored Content
Sponsored Content
Fast News Search
Related News
Massive Losses for Intercell (March 1, 2011)
Intercell Issues Convertible Bond (February 23, 2011)
Intercell Raises Authorized Capital (December 16, 2010)
Serious setback for Intercell (December 14, 2010)
Sponsored Content
Read More
Featured